Support our Foundation of Myology project
1662 news items
Events
Fête de la science from 5 to 10 ctober 2026
On 14/09/2026
Organised annually by the Ministry for Higher Education, Research and Innovation, this event aims to enable everyone to discover the world of science and meet…
Events
MYOLOGY 2027: registration and abstract submission are now open
On 14/09/2026
The 9th International Congress of Myology, MYOLOGY 2027, will take place in Strasbourg from 10 to 13 May 2027. Throughout the four days, leading international…
Events
The teams from the Institute attending the WMS conference
On 14/09/2026
The 31st International Congress of the World Muscle Society (WMS) will take place from 29 September to 3 October 2026 in Hiroshima, Japan. Experts from…
Events
The Institut de Myologie Association is partnering with “Septembre Bouge”, an initiative to promote daily physical activity and sport
On 11/09/2026
In September 2026, France is getting active with the “Septembre Bouge” campaign. Organised jointly by the Ministry of Sport, Youth and Associations, and the Ministry…
Events
2026 edition of the ‘1,000 researchers in schools’ campaign
On 10/09/2026
Now in its 14th year, the ‘1,000 Researchers in Schools in France and Abroad’ initiative will take place from 2 November to 4 December in…
Events
A look back at the Match of the Heroes!
On 10/09/2026
Following this unprecedented charity match in aid of research, held on 31 May with #TeamDesHéros – comprising former Les Verts players and celebrities – at…
Research
Clinical presentations that can sometimes be misleading in women who are carriers of FHL1-related myopathy
On 07/09/2026
French clinicians have compiled the clinical and genetic data of five female patients who were ultimately diagnosed as ‘carriers’ of myopathy linked to the FHL1…
Research
A better understanding of the barriers and enablers of physical activity in myasthenia gravis
On 19/08/2026
Led by Simone Birnbaum, a researcher at the Neuromuscular physiology and neuromuscular Evaluation Lab, in collaboration with the AFM-Telethon, the national MYaEX study involved 455…
Patient care
Significant global disparities in access to innovative treatments for SMA
On 23/07/2026
South African clinicians have compiled and analysed the difficulties in accessing innovative treatments for SMN1-related proximal spinal muscular atrophy in much of the non-Western world:…
Patient care
A combination therapy involving an antisense oligonucleotide and an HDAC6 inhibitor appears promising for SMA
On 21/07/2026
Researchers in Lyon have investigated, both in vitro and in vivo, the potential therapeutic synergy between the type 6 HDAC inhibitor (givinostat), which is already…
Patient care
TK2 deficiency: from the treatment of early-stage forms to the first benefits in late-stage forms
On 16/07/2026
On 31 March 2026, the European Commission granted a marketing authorisation (MA) under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of mitochondrial…
Patient care
Towards a consensus-based integration of innovative therapies for myasthenia gravis?
On 13/07/2026
A group of European specialists in autoimmune myasthenia gravis set out to reach a consensus on the inclusion of new molecules (such as neonatal Fc…
Patient care
The benefits of the ketogenic diet in the treatment of myasthenia gravis
On 10/07/2026
German clinicians have investigated the benefits of the ketogenic diet (very high in fat and low in carbohydrates) in autoimmune myasthenia gravis, following on from…
Research
In myasthenia gravis, complement inhibitors increase life expectancy… and cardiovascular risk!
On 08/07/2026
Two German researchers investigated the benefits and potential complications – particularly cardiovascular ones – of a new class of drugs used to treat refractory forms…
Research
A review of myositis in the NEJM, authored by two French experts
On 24/06/2026
In line with their research over several decades and the advances they have already spearheaded, Professors Olivier Benveniste and Yves Allenbach (the Inflammatory Myopathies &…
Research
Results of the cemdisiran trial in myasthenia gravis have been published
On 22/06/2026
In 13 countries, including France, the Phase III Nimble trial evaluated cemdisiran, a small interfering RNA (siRNA) targeting complement component 5, administered subcutaneously, in patients…
Research
Increasing utrophin expression in DMD using CRISPR-Cas9
On 19/06/2026
One therapeutic approach for Duchenne muscular dystrophy (DMD) involves increasing the expression of utrophin to compensate for the absence of dystrophin, with which it shares…
Patient care
Recommendations for the management of neuropsychiatric disorders associated with DMD
On 16/06/2026
The management of neurodevelopmental and psychiatric disorders represents a major unmet need among patients with Duchenne muscular dystrophy (DMD). As part of the European BIND…
Research
An analysis of BNDMR data on myasthenia gravis
On 16/06/2026
A study of 3,963 patients with myasthenia gravis included in the National Rare Diseases Database (BNDMR) provides valuable insights into patient care at rare disease…
Patient care
Pioglitazone evaluated in inclusion body myositis during a phase I trial
On 15/06/2026
Pioglitazone, a selective agonist of the nuclear PPAR-γ receptors, was evaluated in a phase I trial involving 13 patients with inclusion body myositis, all of…